Back to Browse Journals » International Journal of High Throughput Screening » Volume 1

In vitro screening and structural characterization of inhibitors of the S100B-p53 interaction

Authors Paul T Wilder, Thomas H Charpentier, Melissa A Liriano, et al

Published Date July 2010 Volume 2010:1 Pages 109—126

DOI http://dx.doi.org/10.2147/IJHTS.S8210

Published 7 July 2010

Paul T Wilder1,2, Thomas H Charpentier1, Melissa A Liriano1, Kira Gianni1, Kristen M Varney1, Edwin Pozharski3, Andrew Coop3, Eric A Toth1, Alex D MacKerell3, David J Weber1,2

1Department of Biochemistry and Molecular Biology, The University of Maryland School of Medicine, 2HTS Center, University of Maryland Greenebaum Cancer Center, 3Department of Pharmaceutical Sciences, The University of Maryland School of Pharmacy, MD, USA

Abstract: S100B is highly over-expressed in many cancers, including malignant melanoma. In such cancers, S100B binds wild-type p53 in a calcium-dependent manner, sequestering it, and promoting its degradation, resulting in the loss of p53-dependent tumor suppression activities. Therefore, S100B inhibitors may be able to restore wild-type p53 levels in certain cancers and provide a useful therapeutic strategy. In this regard, an automated and sensitive fluorescence polarization competition assay (FPCA) was developed and optimized to screen rapidly for lead compounds that bind Ca2+-loaded S100B and inhibit S100B target complex formation. A screen of 2000 compounds led to the identification of 26 putative S100B low molecular weight inhibitors. The binding of these small molecules to S100B was confirmed by nuclear magnetic resonance spectroscopy, and additional structural information was provided by X-ray crystal structures of several compounds in complexes with S100B. Notably, many of the identified inhibitors function by chemically modifying Cys84 in protein. These results validate the use of high-throughput FPCA to facilitate the identification of compounds that inhibit S100B. These lead compounds will be the subject of future optimization studies with the ultimate goal of developing a drug with therapeutic activity for the treatment of malignant melanoma and/or other cancers with elevated S100B.

Keywords: nuclear magnetic resonance, fluorescence polarization, melanoma, chlorpromazine, thimerosal, sanguinarine

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

A novel cell-based 384-well, label-free assay for discovery of inhibitors of influenza A virus

Fuli Jia, Clinton Maddox, Alice Gao, et al

International Journal of High Throughput Screening 2010, 1:57-67

Published Date: 12 May 2010

Comparison of the efficiencies of two TR-FRET methods to detect in vitro natural and synthesized inhibitors of the Raf/MEK/ERK signaling pathway

Fabienne Saab, Sylvain Routier, Jean-Yves Mérour, et al

International Journal of High Throughput Screening 2010, 1:81-98

Published Date: 1 June 2010

Progress in antiretroviral drug delivery using nanotechnology

Rama Mallipeddi, Lisa Cencia Rohan

International Journal of Nanomedicine 2010, 5:533-547

Published Date: 22 July 2010

Fungus-mediated biological synthesis of gold nanoparticles: potential in detection of liver cancer

Chauhan A, Zubair S, Tufail S, Sherwani A, Sajid M, Raman SC, Azam A, Owais M

International Journal of Nanomedicine 2011, 6:2305-2319

Published Date: 12 October 2011

Use of a semiquantitative procalcitonin kit for evaluating severity and predicting mortality in patients with sepsis

Kenzaka T, Okayama M, Kuroki S, Fukui M, Yahata S, Hayashi H, Kitao A, Kajii E, Hashimoto M

International Journal of General Medicine 2012, 5:483-488

Published Date: 31 May 2012

Nanostructured polyurethane-poly-lactic- co-glycolic acid scaffolds increase bladder tissue regeneration: an in vivo study

Yao C, Hedrick M, Pareek G, Renzulli J, Haleblian G, Webster TJ

International Journal of Nanomedicine 2013, 8:3285-3296

Published Date: 28 August 2013